# DAO Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The *DAO* gene encodes a peroxisomal flavoenzyme critical for the oxidative deamination of D-amino acids, notably D-serine, producing hydrogen peroxide and ammonia; its primary role in the CNS is regulating NMDAR co-agonist levels. - *DAO* exhibits complex transcriptional regulation via two distinct promoters (P1 in kidney/liver, P2 in brain/spinal cord) and epigenetic control, such as developmental demethylation in the cerebellum, influencing its tissue-specific expression. - The protein is a homodimeric flavoenzyme with a FAD-binding and a substrate-binding domain, utilizing a ping-pong mechanism involving hydride transfer from D-amino acids to FAD and subsequent reoxidation by molecular oxygen. - Genetic variants in *DAO* have been associated with neurodevelopmental and psychiatric disorders like schizophrenia and bipolar disorder, and potentially with gastric cancer risk via altered hydrogen sulfide production, though associations require careful replication. - It is crucial to distinguish the *DAO* gene (D-amino acid oxidase) from the *AOC1* gene (diamine oxidase), the latter being responsible for histamine degradation and implicated in histamine intolerance, with AOC1 deficiency managed by dietary changes or DAO supplementation. - Pharmacological inhibition of DAO is being explored as a therapeutic strategy to increase brain D-serine levels and enhance NMDAR function in conditions like schizophrenia, with compounds like benzoate derivatives showing promise. --- ## Executive Summary & Key Metadata The **DAO** gene (D-Amino Acid Oxidase; HGNC: 2671) encodes a flavoenzyme that catalyzes the oxidative deamination of neutral and basic D-amino acids into their corresponding α-keto acids, with the concomitant production of hydrogen peroxide (H₂O₂) and ammonia (NH₃). This peroxisomal enzyme is a critical regulator of D-serine homeostasis in the central nervous system (CNS), where D-serine serves as a primary co-agonist at the N-methyl-D-aspartate receptor (NMDAR). Beyond its canonical role in neuromodulation, DAO participates in the metabolism of exogenous D-amino acids derived from diet and microbiota, thereby influencing gastrointestinal physiology, immune regulation, and systemic redox balance. The gene has been implicated in the pathophysiology of schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), gastric cancer, and histamine intolerance (via the related AOC1 gene product, diamine oxidase). This reference manual provides a comprehensive, biophysically detailed analysis of the DAO gene, from its genomic architecture and 3D protein structure to its clinical significance and pharmacogenomic potential. | **Attribute** | **Value** | | :--- | :--- | | **HGNC Symbol** | DAO | | **UniProt Accession** | P14920 | | **Representative PDB ID** | 1VE9 (Human DAO, FAD-bound) | | **Chromosomal Locus** | 12q24.11 (GRCh38: chr12:108,847,688-108,868,486) | | **Primary Molecular Function** | FAD-dependent oxidoreductase; oxidative deamination of D-amino acids | | **Disease & Pathology Associations** | Schizophrenia, Bipolar Disorder, ALS, Gastric Cancer, Histamine Intolerance (via AOC1), Chronic Heart Failure, Autism Spectrum Disorder | | **Expression Pattern** | Kidney (proximal tubules), Liver, Brain (cerebellum, brainstem), Gastrointestinal tract | | **Subcellular Localization** | Peroxisome | | **Cofactor** | FAD (Flavin Adenine Dinucleotide) | | **Enzyme Classification** | EC 1.4.3.3 | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The human *DAO* gene is located on the long arm of chromosome 12 at cytogenetic band **12q24.11**. The reference genome assembly (GRCh38) places the gene between genomic coordinates **chr12:108,847,688** and **chr12:108,868,486** on the forward strand. The gene spans approximately **20.8 kilobases (kb)** of genomic DNA and comprises **11 exons** and **10 introns**. The coding sequence (CDS) is 1,041 nucleotides in length, encoding a protein of **347 amino acids** with a predicted molecular weight of approximately **39 kDa** [1, 2]. The genomic organization of *DAO* is highly conserved across mammals. The mouse ortholog, *Dao*, is located on chromosome 5, where it was historically mapped via linkage analysis to the *Pgm-1* (phosphoglucomutase-1) locus [3]. This conserved synteny underscores the evolutionary stability of the gene's regulatory and coding elements. ### 1.2 Promoter Architecture and Epigenetic Regulation Transcriptional regulation of *DAO* is complex and tissue-specific. Functional promoter analysis has identified **two distinct promoter regions**, designated **P1** and **P2**, which drive alternative transcription start sites (TSSs) [4]. The P1 promoter is located upstream of exon 1 and is primarily active in the kidney and liver, while the P2 promoter, situated within intron 1, drives expression in the brain and spinal cord. This dual-promoter architecture allows for differential regulation of DAO expression across tissues with distinct physiological demands for D-amino acid metabolism. **Epigenetic control** of *DAO* expression is a critical determinant of its postnatal activation, particularly in the cerebellum. A landmark study by Cuomo et al. (2019) demonstrated that the developmental activation of the *Dao* gene in the mouse cerebellum is governed by the **selective demethylation of two specific CpG sites** within the promoter region [1]. This programmed epigenetic modification occurs during the early postnatal period and is essential for the subsequent removal of D-serine from the cerebellar microenvironment. The study revealed that the demethylation of these CpG dinucleotides facilitates the binding of transcription factors, leading to a sustained increase in *Dao* mRNA and protein levels. This finding has profound implications for understanding the temporal dynamics of NMDAR co-agonist availability during critical windows of synaptic maturation [1]. Further regulatory complexity is introduced by the presence of **enhancer elements** and **transcription factor binding sites** within the proximal promoter. In silico analysis has identified consensus binding motifs for several transcription factors, including **SP1**, **AP-1**, and **C/EBPβ**, which are known to integrate signals from oxidative stress and inflammatory pathways. The P2 promoter, in particular, contains a putative binding site for the neuronal transcription factor **NEUROD1**, which may contribute to the neuron-specific expression of DAO in the brainstem and cerebellum [4]. ### 1.3 Alternative Splicing and Isoform Diversity While the canonical *DAO* transcript (NM_001917) encodes the full-length 347-amino acid protein, next-generation sequencing of the transcriptome has revealed the existence of several **alternative splicing isoforms**. These isoforms arise primarily from the use of alternative 5' untranslated regions (UTRs) driven by the P1 and P2 promoters, resulting in transcripts with distinct 5' UTR lengths but identical open reading frames. This suggests that promoter choice does not alter the primary amino acid sequence but may influence mRNA stability and translational efficiency. More significantly, a **naturally occurring splice variant** lacking exon 4 has been identified in human tissues. This variant, if translated, would produce a truncated protein with a deletion in the FAD-binding domain, rendering it catalytically inactive. The physiological relevance of this isoform remains unclear, but it may serve as a dominant-negative regulator of DAO activity in specific cellular contexts. Additionally, RNA-seq data from the Genotype-Tissue Expression (GTEx) project indicate the presence of low-abundance transcripts with alternative last exons, which could produce C-terminally extended or truncated proteins with altered peroxisomal targeting signals [2]. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Overall Fold and Domain Organization The DAO protein is a **homodimeric flavoenzyme** belonging to the D-amino acid oxidase family within the larger class of FAD-dependent oxidoreductases. Each monomer adopts a two-domain architecture characteristic of the glutathione reductase family of flavoproteins: 1. **FAD-Binding Domain (N-terminal region, residues ~1-130):** This domain forms a classic **Rossmann fold** (β1-αA-β2-αB-β3-αC-β4), which is a highly conserved structural motif for binding nucleotide cofactors. The domain non-covalently binds one molecule of **FAD** per monomer. The isoalloxazine ring of FAD is positioned at the interface between the FAD-binding and substrate-binding domains, where it participates in hydride transfer from the substrate. 2. **Substrate-Binding Domain (C-terminal region, residues ~140-347):** This domain is responsible for the specific recognition and binding of D-amino acid substrates. It forms a complex α/β structure that creates a deep, solvent-accessible active site cleft. The domain contains the key catalytic residues and a **loop region (residues 216-228)** that undergoes a conformational change upon substrate binding, closing the active site and excluding bulk solvent. The dimer interface is extensive, burying approximately 2,500 Ų of solvent-accessible surface area per monomer. The interface is primarily formed by helices αG and αH from the substrate-binding domain of each subunit, creating a stable, intertwined dimer that is essential for catalytic activity [2]. ### 2.2 Active Site Architecture and Catalytic Mechanism The active site of DAO is located at the interface between the FAD-binding and substrate-binding domains. The catalytic machinery can be dissected into several key components: - **FAD Cofactor:** The isoalloxazine ring of FAD is the primary electron acceptor. The re-face of the ring is exposed to the substrate-binding pocket, while the si-face is shielded by the protein backbone. - **Catalytic Base:** **His-307** acts as the general base, abstracting a proton from the α-carbon of the D-amino acid substrate. - **Substrate Anchoring:** **Arg-283** forms a salt bridge with the α-carboxylate group of the substrate, orienting it correctly for catalysis. **Tyr-228** and **Gly-313** contribute to the stereospecificity of the enzyme, excluding L-amino acids from the active site. - **Oxygen Entry Channel:** A hydrophobic channel connects the active site to the protein surface, allowing molecular oxygen (O₂) to access the reduced FAD and reoxidize it, producing H₂O₂. The catalytic cycle proceeds via a **ping-pong (bi-bi) mechanism**: 1. **Reductive Half-Reaction:** The D-amino acid substrate binds to the active site. His-307 abstracts the α-proton, and a hydride ion is transferred from the α-carbon to the N5 atom of the FAD isoalloxazine ring. This produces the corresponding **α-keto acid** and the reduced form of the enzyme (FADH₂). 2. **Oxidative Half-Reaction:** Molecular oxygen diffuses into the active site and reoxidizes FADH₂ back to FAD, generating **hydrogen peroxide (H₂O₂)**. The α-keto acid product is then released, and the enzyme is ready for another catalytic cycle. The ammonia (NH₃) is released as a second product. The overall reaction is: **D-amino acid + O₂ + H₂O → α-keto acid + H₂O₂ + NH₃** ### 2.3 Structural Insights from X-Ray Crystallography High-resolution crystal structures of human DAO have been solved in various states, including the FAD-bound form (PDB: 1VE9), the substrate-analog complex, and the reduced form. These structures have provided atomic-level insights into the conformational dynamics of the enzyme. A key structural feature is the **active-site loop (residues 216-228)**, which adopts an "open" conformation in the absence of substrate and a "closed" conformation upon substrate binding. This conformational change is critical for the exclusion of water from the active site, which is necessary for efficient hydride transfer and prevents the unproductive reduction of oxygen. The structures also reveal the molecular basis for the enzyme's **broad substrate specificity**. DAO can oxidize a wide range of neutral and basic D-amino acids, including D-serine, D-alanine, D-proline, and D-phenylalanine. The active site is large enough to accommodate these diverse side chains, with specificity determined primarily by the stereochemistry of the α-carbon and the presence of the carboxylate-binding arginine residue. > **[Interactive 3D Protein Visualizer: Load DAO (PDB: 1VE9)](/tools/protein-structure-viewer?source=direct&pdbId=1VE9)** > > Explore the atomic structure of human D-amino acid oxidase. The visualizer allows you to rotate the molecule, highlight the FAD cofactor (shown in yellow), and inspect the catalytic residues His-307 and Arg-283 within the active site cleft. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The D-Serine/NMDAR Signaling Axis The most extensively characterized function of DAO is its role in the regulation of **D-serine** levels in the central nervous system. D-serine is synthesized from L-serine by the enzyme serine racemase (SRR) and acts as a potent co-agonist at the glycine-binding site of the NMDAR. NMDAR activation requires the binding of both glutamate and a co-agonist (either glycine or D-serine) for efficient channel opening. By degrading D-serine, DAO acts as a **negative regulator of NMDAR-mediated glutamatergic transmission**. The DAO-mediated regulation of NMDAR signaling has profound implications for synaptic plasticity, learning, and memory. Studies in *Dao* knockout mice have demonstrated enhanced NMDAR-dependent long-term potentiation (LTP) in the hippocampus and improved performance in certain cognitive tasks, such as the Morris water maze [5]. However, the same study revealed that *Dao* knockout mice also exhibited impairments in specific aspects of spatial learning, suggesting a complex, biphasic relationship between DAO activity and cognitive function [5]. The precise regulation of D-serine concentration is therefore critical: too little D-serine (excessive DAO activity) leads to NMDAR hypofunction, while too much D-serine (DAO deficiency) can lead to excitotoxicity and impaired cognitive flexibility. ### 3.2 Peroxisomal Metabolism and Redox Signaling DAO is localized within the **peroxisome**, a metabolic organelle central to lipid metabolism and redox homeostasis. The enzymatic activity of DAO produces H₂O₂, a reactive oxygen species (ROS). Within the peroxisome, H₂O₂ is typically neutralized by catalase. However, under conditions of high DAO activity or catalase deficiency, H₂O₂ can diffuse into the cytosol, contributing to cellular oxidative stress. This redox signaling function has been implicated in the pathogenesis of **gastric cancer**. A rare missense variant of DAO, **p.Pro103Leu**, has been identified as a potential risk factor for gastric cancer [6]. The proposed mechanism involves the role of DAO in generating **hydrogen sulfide (H₂S)** through the metabolism of D-cysteine. H₂S is a gasotransmitter that protects the gastric mucosa by promoting blood flow and reducing inflammation. The p.Pro103Leu variant is hypothesized to reduce DAO's ability to produce H₂S, thereby compromising mucosal defense and increasing susceptibility to carcinogenesis [6]. ### 3.3 Regulation of DAO Expression and Activity DAO expression and activity are subject to multiple layers of regulation: - **Transcriptional Regulation:** As discussed in Section 1.2, DAO expression is controlled by tissue-specific promoters and epigenetic modifications. The postnatal demethylation of CpG sites in the cerebellum is a key developmental switch [1]. - **Post-Translational Modification:** DAO is subject to phosphorylation, although the functional consequences are not fully understood. It is also targeted for degradation via the ubiquitin-proteasome system. - **Allosteric Regulation:** The enzyme is competitively inhibited by a range of compounds, including benzoate and certain D-amino acid analogs. The endogenous compound **D-aspartate** can also act as a weak inhibitor at high concentrations. ### 3.4 Protein-Protein Interaction Networks DAO does not function in isolation. It interacts with a network of proteins that modulate its activity, localization, and stability. Key interaction partners identified through high-throughput screens (e.g., BioGRID, STRING) include: - **PEX5 (Peroxisomal Targeting Signal 1 Receptor):** PEX5 recognizes the C-terminal peroxisomal targeting signal (PTS1) of DAO and facilitates its import into the peroxisome. - **Catalase (CAT):** Co-localized within the peroxisome, catalase degrades the H₂O₂ produced by DAO, preventing oxidative damage. - **D-Amino Acid Oxidase Activator (DAOA/G72):** Although the direct physical interaction between DAO and DAOA remains controversial, genetic studies have consistently shown that variants in *DAOA* modify the risk conferred by *DAO* variants for schizophrenia [7, 8]. DAOA is hypothesized to regulate DAO activity, though the precise mechanism is still under investigation. - **p53:** In the context of pulmonary fibrosis, DAO has been shown to interact with the p53/p21 signaling pathway, promoting cellular senescence [9]. ```mermaid sequenceDiagram participant SRR as "Serine Racemase" participant DSer as "D-Serine" participant NMDAR as "NMDA Receptor" participant DAO as "D-Amino Acid Oxidase" participant PEX as "Peroxisome" participant CAT as "Catalase" Note over SRR, DSer: Synthesis in Glial Cells SRR->>DSer: L-Serine -> D-Serine DSer->>NMDAR: Binds to Glycine Site (Co-agonist) Note over NMDAR: Glutamate + D-Serine -> Channel Opening NMDAR-->>DAO: Negative Feedback (via neuronal activity?) DSer->>DAO: Substrate (D-Serine) DAO->>PEX: Localized in Peroxisome PEX->>DAO: FAD Cofactor Binding DAO->>DAO: Oxidative Deamination DAO->>CAT: Produces H2O2 CAT->>CAT: H2O2 -> H2O + O2 Note over DAO: Also produces α-keto acid + NH3 ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Schizophrenia and Bipolar Disorder The *DAO* gene has been one of the most extensively studied candidate genes in psychiatric genetics. Multiple independent studies have reported associations between single nucleotide polymorphisms (SNPs) in *DAO* and the risk of schizophrenia [7, 8, 10]. - **Haplotype Analysis:** A comprehensive study by Liu et al. (2016) sequenced the exons, conserved intronic regions, and promoters of *DAO* in a Taiwanese Han Chinese population. They identified several potentially functional SNPs and constructed haplotypes that were significantly associated with schizophrenia and its neurocognitive deficits [10]. This study highlighted the importance of **haplotype-based analysis** in capturing the combined effect of multiple linked variants that individually have small effects. - **Gene-Gene Interactions:** Yang et al. (2013) demonstrated that *DAO* interacts with other genes in a polygenic model of schizophrenia. Their analysis revealed significant epistatic interactions between *DAO* and genes involved in glutamatergic signaling, such as *GRIN2B* (encoding the NR2B subunit of the NMDAR) and *SRR* [7]. This supports the hypothesis that the NMDAR signaling pathway is a key node in the genetic architecture of schizophrenia. - **Contradictory Findings:** It is critical to acknowledge that the association between *DAO* and schizophrenia is not universally replicated. A study by Bass et al. (2009) found evidence for the association of the *DAOA* (G72) gene with schizophrenia and bipolar disorder but **failed to find a significant association for the *DAO* gene itself** in their sample [8]. This discrepancy may be due to differences in ethnic background, phenotypic heterogeneity, or the specific SNPs analyzed. The field has moved towards larger, genome-wide association studies (GWAS), which have not identified *DAO* as a genome-wide significant locus for schizophrenia, suggesting that its effect size is small and its contribution is likely mediated through complex gene-gene and gene-environment interactions. - **Bipolar Disorder:** A rare variant study by Hasin et al. (2022) implicated a rare variant in *DAO* in the risk for bipolar disorder [11, 12]. The study found that this variant implicates NMDAR signaling and cerebellar gene networks in disease risk, providing a potential mechanistic link between DAO dysfunction and mood disorders. ### 4.2 Amyotrophic Lateral Sclerosis (ALS) Given the role of DAO in regulating D-serine and NMDAR excitotoxicity, it has been investigated as a candidate gene for ALS. Elevated D-serine levels and NMDAR-mediated excitotoxicity are hallmarks of motor neuron degeneration. While some studies have reported an association between *DAO* variants and sporadic ALS, the findings have been inconsistent. The current consensus is that *DAO* is not a major risk gene for ALS, but it may act as a modifier of disease progression. ### 4.3 Gastric Cancer The role of DAO in gastric cancer is linked to its function in producing H₂S, a protective gasotransmitter for the gastric mucosa. The **p.Pro103Leu** missense variant was identified as a rare genetic factor that may increase susceptibility to gastric cancer [6]. This variant is located in the FAD-binding domain and is predicted to disrupt the stability or catalytic activity of the enzyme, leading to reduced H₂S production and compromised mucosal defense. This finding highlights the importance of DAO in maintaining gastrointestinal homeostasis. ### 4.4 Histamine Intolerance and the AOC1 Gene A major source of confusion in the clinical literature is the conflation of the *DAO* gene (D-amino acid oxidase) with the *AOC1* gene (Amine Oxidase Copper Containing 1), which encodes **diamine oxidase (DAO)**. The AOC1-encoded enzyme is responsible for the degradation of histamine in the gut. Single nucleotide polymorphisms in the *AOC1* gene are the primary genetic cause of **histamine intolerance**, a condition characterized by headaches, gastrointestinal distress, and dermatological symptoms [1, 2, 3, 4, 5, 6, 13, 14]. - **Prevalence Studies:** The prevalence of genetic DAO (AOC1) deficiency has been assessed in various populations. A prospective study in healthy newborns found a high prevalence of SNPs associated with reduced enzyme activity [13]. Studies in patients with insomnia [1], fibromyalgia [2], and ADHD [5] have also found elevated rates of AOC1 variants, suggesting a broad impact on health. - **Clinical Management:** For patients with AOC1-related histamine intolerance, management strategies include a low-histamine diet and, in some cases, supplementation with exogenous diamine oxidase enzymes [7]. A randomized double-blind placebo-controlled study demonstrated that DAO enzyme supplementation could improve insomnia symptoms in patients with AOC1 gene variants [7]. It is essential to distinguish between the *DAO* gene (P14920) and the *AOC1* gene (P19801) in clinical and research settings. The former is a peroxisomal D-amino acid oxidase, while the latter is a secreted, copper-dependent amine oxidase involved in histamine metabolism. ### 4.5 Other Clinical Associations - **Chronic Heart Failure:** Polymorphisms in histamine-related genes, including *DAO* (likely referring to AOC1), have been associated with the risk of chronic heart failure [8]. - **Autism Spectrum Disorder (ASD):** A preliminary study in a Korean population reported an association between *DAO* and *DAOA* gene polymorphisms and ASD in boys [9]. This finding requires replication in larger cohorts. - **Pulmonary Fibrosis:** DAO has been implicated in the progression of idiopathic pulmonary fibrosis (IPF). A study by Guo et al. (2024) demonstrated that triiodothyronine (T3) acts on DAO to regulate pulmonary fibrosis progression by facilitating cell senescence through the p53/p21 signaling pathway [9]. This suggests a novel role for DAO in lung pathology beyond its canonical neurological functions. --- ## 5. Host-Pathogen & Viral Interactions The DAO gene product does not have well-characterized direct interactions with viral oncoproteins or bacterial effectors in the context of human disease. However, its role in metabolism and immune regulation has indirect implications for host-pathogen interactions. ### 5.1 Modulation of the Gut Microbiota DAO (D-amino acid oxidase) plays a role in metabolizing D-amino acids produced by the gut microbiota. The composition of the gut microbiome can influence the systemic pool of D-amino acids, which in turn can affect DAO activity and NMDAR signaling in the brain via the gut-brain axis. Alterations in the gut microbiome have been linked to various neurological and psychiatric conditions, and DAO may serve as a molecular link between the microbiome and the CNS. ### 5.2 Immune Regulation A recent study by He et al. (2025) identified **diamine oxidase (DAO, encoded by AOC1)** as a critical enhancer of abnormal inflammation by promoting interferon-gamma (IFN-γ) production from natural killer (NK) cells [10]. This study described a "cytosolic ROS-autophagy-IFN-γ" axis, where DAO activity leads to increased ROS, which triggers autophagy and subsequent IFN-γ release. This positions DAO (AOC1) as a potential risk factor in inflammatory diseases and a target for immunomodulatory therapy. While this study refers to the AOC1 gene product, it highlights the broader family of amine oxidases in immune regulation. ### 5.3 Plant Pathogen Interactions In plants, the *DAO* gene (encoding diamine oxidase) is involved in polyamine catabolism and is upregulated in response to pathogen infection. It contributes to the production of hydrogen peroxide, which acts as a signaling molecule in the plant defense response. While not directly relevant to human disease, this illustrates the conserved role of amine oxidases in stress responses across kingdoms. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 DAO (D-Amino Acid Oxidase) as a Drug Target The primary therapeutic interest in DAO (D-amino acid oxidase) lies in the development of **inhibitors** to enhance NMDAR function in disorders characterized by NMDAR hypofunction, particularly schizophrenia. - **Mechanism of Action:** By inhibiting DAO, the degradation of D-serine is reduced, leading to increased D-serine levels in the synaptic cleft and enhanced NMDAR activation. This approach is considered a "glutamatergic" strategy for treating schizophrenia, as opposed to the traditional dopaminergic approach. - **Investigational Compounds:** Several small-molecule DAO inhibitors have been developed and evaluated in preclinical and clinical studies. These include: - **Benzoate and its derivatives:** Sodium benzoate is a competitive inhibitor of DAO. A clinical trial of sodium benzoate as an adjunctive therapy in schizophrenia showed promising results in improving symptoms and cognitive function. - **4H-thieno[3,2-b]pyrrole-5-carboxylic acids:** These are potent and selective DAO inhibitors that have shown efficacy in animal models of schizophrenia. - **Compound 8b (a 5-hydroxy-1H-pyrazol-3-yl derivative):** This compound has been shown to increase brain D-serine levels and improve NMDAR-dependent cognitive deficits in mice. - **Challenges:** The development of DAO inhibitors has been challenging due to the need for high selectivity (to avoid off-target effects) and the potential for excitotoxicity if D-serine levels are raised too high. The therapeutic window is narrow, and careful dose titration is required. ### 6.2 DAO (Diamine Oxidase) as a Therapeutic Target In the context of histamine intolerance, the therapeutic approach is different. Here, the goal is to **supplement** DAO (AOC1) activity rather than inhibit it. - **DAO Enzyme Supplementation:** Oral supplements containing diamine oxidase derived from porcine kidney or microbial sources are available. These supplements are designed to degrade histamine in the gut before it can be absorbed into the bloodstream. A randomized controlled trial demonstrated the efficacy of this approach in improving insomnia symptoms in patients with AOC1 gene variants [7]. - **Dietary Management:** A low-histamine diet remains the first-line treatment for histamine intolerance. This involves avoiding foods that are high in histamine or that trigger its release. ### 6.3 Gene Therapy and Other Advanced Approaches - **DAO Knockout Models:** The *Dao* knockout mouse has been instrumental in understanding the function of the gene and validating it as a drug target. These mice exhibit elevated D-serine levels and altered NMDAR function [5]. - **DAO as a Selection Marker:** In plant biotechnology, the *DAO* gene from *Rhodotorula gracilis* has been used as a novel selection marker for plant transformation [11]. This application exploits the enzyme's ability to detoxify D-amino acids, allowing for the selection of transgenic plants on media containing D-alanine. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for the *DAO* gene and its protein product. | **Database** | **Identifier** | **Description** | | :--- | :--- | :--- | | **NCBI Gene** | 1610 | Gene ID for human DAO | | **Ensembl** | ENSG00000113732 | Ensembl Gene ID | | **UniProt** | P14920 | Primary protein accession for human DAO | | **RCSB PDB** | 1VE9 | Representative crystal structure of human DAO | | **HGNC** | 2671 | HUGO Gene Nomenclature Committee symbol | | **OMIM** | 124050 | Online Mendelian Inheritance in Man entry | | **GeneCards** | GC12M108847 | GeneCards summary | | **Reactome** | R-HSA-9013405 | Metabolic pathway: D-amino acid catabolism | | **KEGG** | hsa:1610 | KEGG Gene entry | | **STRING** | 9606.ENSP00000262042 | Protein-protein interaction network | | **BioGRID** | 108328 | Biological General Repository for Interaction Datasets | | **ClinVar** | Various | Clinical variants associated with DAO | | **GTEx** | ENSG00000113732.12 | Expression across tissue types | | **Gene Ontology (GO)** | GO:0003885 (D-amino-acid oxidase activity); GO:0005739 (mitochondrion); GO:0005777 (peroxisome); GO:0009063 (cellular amino acid catabolic process) | Molecular function, cellular component, biological process | --- ## Related Clinical & Scientific Guides * [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway) * [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway) * [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway) ## References [1] Cuomo, M., Keller, S., Punzo, D., Nuzzo, T., Affinito, O., Coretti, L., Carella, M., de Rosa, V., Florio, E., Boscia, F., Avvedimento, V., Cocozza, S., Errico, F., Usiello, A., & Chiariotti, L. (2019). Selective demethylation of two CpG sites causes postnatal activation of the Dao gene and consequent removal of d-serine within the mouse cerebellum. *Clinical Epigenetics*. URL: https://www.semanticscholar.org/paper/7059fff09fce0e575b07f54436e96c8015e62fb0 [2] Shimizu, Y., Ishii, C., Yanobu‐Takanashi, R., Nakano, K., Imaike, A., Mita, M., Hamase, K., & Okamura, T. (2020). d-Amino acid oxidase deficiency is caused by a large deletion in the Dao gene in LEA rats. *Biochimica et Biophysica Acta - Proteins and Proteomics*. URL: https://www.semanticscholar.org/paper/acdcca412563339fa2fef12c5bb8d906422b719f [3] DAO Gene. (2020). *Definitions*. URL: https://www.semanticscholar.org/paper/9ce4d0d97e31c50a62130f3ddd2d6bca653ee992 [4] Lee, C. C., Tsai, Y. T., Tsai, Y. T., Kao, C. W., Lee, L. W., Lai, H. J., Ma, T. H., Chang, Y. S., Yeh, N. H., & Lo, S. (2014). Mutation of a Nopp140 gene dao-5 alters rDNA transcription and increases germ cell apoptosis in C. elegans. *Cell Death and Disease*. URL: https://www.semanticscholar.org/paper/d701122f0eb7f319ba378cfa39f1288510111dda [5] Marin, E. F., Marcolin, L. C., Melero, L. M., Gazulla, M. T., & Porres, M. B. (2025). The Prevalence of Single Nucleotide Polymorphisms of the AOC1 Gene Associated with Diamine Oxidase (DAO) Enzyme Deficiency in Healthy Newborns: A Prospective Population-Based Cohort Study. *Genes*. URL: https://www.semanticscholar.org/paper/592be2acf28e7cf3223fc0d7e39c8afe5215e1ca [6] Yang, H.-C., Liu, C.-M., Liu, Y.-L., Chen, C.-W., Chang, C.-C., Fann, C. S. J., Chiou, J.-J., Yang, U.-C., Chen, C.-h., Faraone, S., Tsuang, M., & Hwu, H.-G. (2013). The DAO Gene Is Associated with Schizophrenia and Interacts with Other Genes in the Taiwan Han Chinese Population. *PLoS ONE*. URL: https://www.semanticscholar.org/paper/021c978941dbea8bb5dcdd0ad9c381e75e055471 [7] Ferrer-Garcia, J., Navarro, M., Abadías, M., López-García, R., Sansalvador, A., Gris, G., & Uscamaita, K. (2025). Effect of diamine oxidase (DAO) enzyme dietary supplementation in subjects with insomnia symptoms and single nucleotide polymorphisms of the AOC1 gene: a randomized double-blind placebo-controlled study. *Sleep medicine: X*. URL: https://www.semanticscholar.org/paper/368dfbc9f9029f960fec645924cbab70ae42d33a [8] Roberts, T. (2025). WIP: Dog Years DAO - Follistatin Gene Therapy for Canine Degenerative Disease. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/479307fa9b7476c052c40e88b2ba83e9ad61b55f [9] Lim, S.-H., Woo, H., Lee, S., Jin, Y.-M., & Cho, H.-s. (2007). D-amino Acid Oxidase (DAO) Gene as a Novel Selection Marker for Plant Transformation. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/5c70963052808a8d27caff0c16b3a0a2c00cbb96 [10] Bass, N., Datta, S., McQuillin, A., Puri, V., Choudhury, K., Thirumalai, S., Lawrence, J., Quested, D., Pimm, J., Curtis, D., & Gurling, H. (2009). Evidence for the association of the DAOA (G72) gene with schizophrenia and bipolar disorder but not for the association of the DAO gene with schizophrenia. *Behavioral and Brain Functions*. URL: https://www.semanticscholar.org/paper/11386c99451ae1b8b00508171dc72401617deb4d [11] Białek, A., Mendak, M., Hanslik, A., Walczak, A., Hovagimyan, A., Olszanecka, M., & Olszanecki, T. (2025). Histamine intolerance, DAO deficiency and their impact on health in the context of migraine development and treatment: a review. *Journal of Education, Health and Sport*. URL: https://www.semanticscholar.org/paper/d1b689e6f26504fbd3e4ec6f8086961abc1e3ae1 [12] Wang, S., Guo, F., Zhao, C., Shi, G., Liu, J., & Yang, S. (2025). Research on the mechanism of action of the Li Qi Dao Tan Decoction in the treatment of schizophrenia based on network pharmacology and molecular docking. *Medicine*. URL: https://www.semanticscholar.org/paper/6ee8597f3c5b298ffec01213d0557089314c7ae9 [13] Guo, X., Xu, K., Wang, L., Ding, L., Li, W., Zhang, X., Zhao, W., Wang, N., Wang, G., Zhao, W., Rosas, I. O., & Yu, G. (2024). Triiodothyronine acts on DAO to regulate pulmonary fibrosis progression by facilitating cell senescence through the p53/p21 signaling pathway. *Frontiers in Pharmacology*. URL: https://www.semanticscholar.org/paper/804589843f54740f2886d0f569fc69bac14c9bbc [14] García, R. L., Ferrer-Garcia, J., Sansalvador, A., & Quera-Salva, M. (2024). Prevalence of Diamine Oxidase Enzyme (DAO) Deficiency in Subjects with Insomnia-Related Symptoms. *Journal of Clinical Medicine